Sanofi India Ltd. (SIL) has demonstrated a strong financial performance for the fourth quarter of 2024, with notable increases in revenue and EBITDA. The company's board has also recommended a final dividend of ₹117 per equity share, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Financial Highlights for Q4 2024
- Revenue Growth: Sanofi India's revenue for Q4 2024 rose by 9.7% year-on-year (YoY), reaching ₹514.9 crore compared to ₹469.2 crore in the same quarter of the previous year.
- EBITDA Increase: The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew by 18.8% YoY, amounting to ₹118.3 crore, up from ₹99.6 crore in Q4 2023.
- Operating Margins: Operating margins improved to 23% in Q4 2024, up from 21.2% in the corresponding quarter of the previous year.
- Net Profit Decline: Despite the positive revenue and EBITDA figures, the net profit declined by 33.7% YoY to ₹91.3 crore, down from ₹137.7 crore in Q4 2023.
Dividend Announcement
The board of Sanofi India has recommended a final dividend of ₹117 per equity share of ₹10 face value for the financial year ending December 31, 2024. This recommendation is subject to approval by the shareholders at the forthcoming AGM. The dividend, if approved, will be paid to shareholders whose names appear in the register of members as of the record date.
Strategic Developments
Sanofi India has been actively expanding its presence in the cardiovascular (CV) and central nervous system (CNS) segments. The company reports that its partnerships in these areas have met expectations, setting the stage for further growth.
Additionally, Sanofi India continues to advance its 'India for India' strategy, focusing on go-to-market initiatives, operational efficiency, and innovation. The successful launch of Soliqua®, a diabetes medication for the premix segment, has been well-received in the market.
About Sanofi India
Sanofi India, a subsidiary of the global healthcare company Sanofi, has been operating in India for nearly seven decades. The company remains committed to expanding its product availability and driving efficiency improvements across its operations.
Recent Developments
In February 2025, Sanofi Consumer Healthcare India, a division of Sanofi India, announced a final dividend of ₹55 per equity share for the financial year ending December 31, 2024. This dividend is also subject to shareholder approval at the upcoming AGM. (goodreturns.in)
Conclusion
Sanofi India's Q4 2024 financial results reflect a strong performance with significant growth in revenue and EBITDA. The recommended final dividend underscores the company's commitment to delivering value to its shareholders. With strategic initiatives in place and a focus on innovation, Sanofi India is well-positioned for continued growth in the Indian pharmaceutical market.
For more detailed information, please refer to Sanofi India's official financial results page. (sanofi.com)
Check out the Latest Football Transfer news – Football Transfer News
Trendy News – Trendy News
Footy Stats - Head to Head Football Match Analysis – Footy Stats
Please note that financial figures and dividend recommendations are subject to change and should be verified with official company communications.